Nuclear E-cadherin and VHL immunoreactivity are prognostic indicators of clear-cell renal cell carcinoma (Q40074094)

17 September 2017

Nuclear E-cadherin and VHL immunoreactivity are prognostic indicators of clear-cell renal cell carcinoma (English)

1 reference

Erratum: Nuclear E-cadherin and VHL immunoreactivity are prognostic indicators of clear-cell renal cell carcinoma

17 September 2017

corrigendum / erratum

1 reference

DOI

10.1038/LABINVEST.2008.9

12 July 2019

http://api.crossref.org/works?select=update-to&filter=doi:10.1038/LABINVEST.2008.9

5

Brenda L Gallie

1 reference

17 September 2017

Michelle L Gervais

1

1 reference

17 September 2017

Pauline C Henry

2

1 reference

17 September 2017

Arthy Saravanan

3

1 reference

17 September 2017

T Nadine Burry

4

1 reference

17 September 2017

Michael A S Jewett

6

1 reference

17 September 2017

Richard P Hill

7

1 reference

17 September 2017

Andrew J Evans

8

1 reference

17 September 2017

Michael Ohh

9

1 reference

17 September 2017

1 October 2007

1 reference

17 September 2017

Laboratory Investigation

1 reference

17 September 2017

87

1 reference

17 September 2017

1252-1264

1 reference

17 September 2017

12

1 reference

https://scigraph.springernature.com/pub.10.1038/labinvest.3700684

17 September 2017

0 references

cites work

Renal cell carcinoma: current status and emerging therapies

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700684

Expression of adipose differentiation-related protein: a predictor of cancer-specific survival in clear cell renal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700684

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700684

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700684

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700684

The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700684

Molecular basis of the VHL hereditary cancer syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700684

Tumour suppression by the human von Hippel-Lindau gene product

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700684

Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700684

Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700684

Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700684

Convergence of Wnt, beta-catenin, and cadherin pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700684

Regulation of E-cadherin expression by VHL and hypoxia-inducible factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700684

VHL promotes E2 box-dependent E-cadherin transcription by HIF-mediated regulation of SIP1 and snail

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700684

Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700684

ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and beta-catenin translocation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700684

Regulation of cadherin adhesive activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700684

Breaking up the tie: disintegrin-like metalloproteinases as regulators of cell migration in inflammation and invasion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700684

Cleavage and shedding of E-cadherin after induction of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700684

Soluble E-cadherin fragments increased in circulation of cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700684

Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700684

pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700684

The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700684

Human HIF-3alpha4 is a dominant-negative regulator of HIF-1 and is down-regulated in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700684

Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700684

Formation of the VHL-elongin BC tumor suppressor complex is mediated by the chaperonin TRiC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700684

Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700684

A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700684

Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700684

Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700684

Tumor suppression by the von Hippel-Lindau protein requires phosphorylation of the acidic domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700684

The Hsp70 and TRiC/CCT chaperone systems cooperate in vivo to assemble the von Hippel-Lindau tumor suppressor complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700684

Diverse effects of mutations in exon II of the von Hippel-Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependent ubiquitin ligase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700684

The role of VHL in the regulation of E-cadherin: a new connection in an old pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700684

A presenilin-1/gamma-secretase cleavage releases the E-cadherin intracellular domain and regulates disassembly of adherens junctions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700684

Nuclear localization and possible functions of receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700684

Gamma-secretase-mediated proteolysis in cell-surface-receptor signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700684

Presenilin-dependent processing and nuclear function of gamma-protocadherins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700684

Notch signaling, gamma-secretase inhibitors, and cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700684

Characterization of soluble E-cadherin as a disease marker in gastric cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700684

Urinary concentrations of the soluble adhesion molecule E-cadherin and total protein in patients with bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700684

Plasmin produces an E-cadherin fragment that stimulates cancer cell invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700684

Cysteine cathepsins and the cutting edge of cancer invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700684

Kallikrein 7 enhances pancreatic cancer cell invasion by shedding E-cadherin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700684

Association of extracellular cleavage of E-cadherin mediated by MMP-7 with HGF-induced in vitro invasion in human stomach cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700684

Engagement of collagen-binding integrins promotes matrix metalloproteinase-9-dependent E-cadherin ectodomain shedding in ovarian carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700684

Change of E-cadherin by hepatocyte growth factor and effects on the prognosis of hypopharyngeal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700684

The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700684

Inactivation of von Hippel-Lindau gene induces constitutive phosphorylation of MET protein in clear cell renal carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700684

Overexpression of the met/HGF receptor in renal cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700684

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700684

7 January 2021

Multi-institutional validation of a new renal cancer-specific survival nomogram

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700684

7 January 2021

Calcium influx triggers the sequential proteolysis of extracellular and cytoplasmic domains of E-cadherin, leading to loss of beta-catenin from cell-cell contacts

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700684

7 January 2021

Expression of MUC1 (EMA) and E-cadherin in renal cell carcinoma: a systematic immunohistochemical analysis of 188 cases

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700684

7 January 2021

VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700684

7 January 2021

Soluble 80-kd fragment of cell-CAM 120/80 disrupts cell-cell adhesion

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700684

7 January 2021

Biological role of HGF/MET pathway in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700684

7 January 2021

10.1038/LABINVEST.3700684

Identifiers

DOI

1 reference

Dimensions Publication ID

17 September 2017

0 references

1 reference